New Seasonal and Perennial Rhinitis Intranasal Treatment Submitted for US and European Marketing Approval.

PR Newswire Europe, July, 2006

LONDON, July 27 /PRNewswire/ --

- Allermist(TM) / Avamys(TM) (fluticasone furoate) Significantly Improved Symptoms of Seasonal and Perennial Allergic Rhinitis in Clinical Studies

GlaxoSmithKline (GSK) today announced it has submitted applications for both U.S. and European marketing approval for a new medicine to treat the symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). The medicine (fluticasone furoate) is an enhanced affinity intranasal corticosteroid with the proposed name of Allermist(TM) in the US and Avamys(R) in Europe.

The efficacy and safety of Allermist / Avamys have been evaluated in seven clinical trials with 2,555 adult and pediatric patients two years of age and older with symptoms of SAR...